Abstract: The present invention relates to furazidin for vaginal use in the treatment of a bacterial vaginal infection. Preferably, the bacterial vaginal infection is caused by Gardnerella vaginalis and/or Atopobium vaginae bacteria.

Abstract: An object of the present invention is to solve inhibition of biopolymer measurement in a nanopore, which involves three-dimensional conformation of a biopolymer containing a nucleic acid. The present invention provides a device for analyzing a biopolymer containing a nucleic acid, the device including: an array device including a plurality of thin film parts having a nanopore; a single common container and a plurality of individual containers capable of storing a measurement solution which is brought into contact with the thin films; and individual electrodes respectively provided in the plurality of individual containers, wherein: the measurement solution is introduced into each of the individual containers and the common container so as to be brought into contact with the thin films; and the measurement solution has a pH equal to or greater than pKa of a guanine base and contains cesium ions as electrolyte cations.

Abstract: An object of the present invention is to provide an enteral nutrition that is simply injected and suppresses gastro-esophageal reflux. The present invention provides an enteral nutrition comprising 0.1 to 1.0 mass % of alginic acid and/or sodium salt thereof, calcium, and 0.1 to 3.5 parts by mass of a chelating agent per part by mass of the calcium.

Abstract: The present invention provides a method for preparing a film comprising a high amount of a sildenafil free base uniformly dispersed therein and having a suitable thickness and size, as well as flexibility providing good handling stability and being not prone to breaking. The present invention also provides a sildenafil free base-containing film prepared from the method.

Abstract: The present invention provides formulas of elemental compositions encompassing acetate salts of calcium, magnesium and zinc along with vitamin D3. The acetate salts could be extracted from natural sources such as pearls, coral, and oyster or compounded using synthetic materials. The dosage and ratio of calcium to magnesium was estimated using in vitro and in vivo estimations. The dosage for promoting bone health and alleviation of osteoporosis is about a quarter to a third of the conventional dose.

Abstract: A gastric ulcer therapeutic agent comprising as an active ingredient a composite hydroxide of a hydrotalcite and an aluminum hydroxide compound, which composite hydroxide is represented by the formula (1), Mg1-xAlx(OH)2+x-ny(An-)y(H2O)m??(1), wherein An-represents an anion, n represents a valence of the anion in the range of 1 to 4, x is in the range of 0.34<x<0.7, y is in the range of 0<y<0.8, and m is in the range of 0<m<4.

Abstract: Hydrotalcite particles having an extremely small average secondary particle diameter and a production process therefor. A resin composition comprising hydrotalcite fine particles and having excellent transparency and a molded article thereof. The hydrotalcite fine particles have an average secondary particle diameter measured by a dynamic light scattering method of 5 to 100 nm.

Abstract: An antimicrobial solution for disinfecting instruments in an automatic sterilization device, the solution comprising: a peracid reaction product formed in situ from combining a liquid acetyl donor with a solid source of peroxide, wherein the in situ reaction takes place in the sterilization device, along with a containment and delivery ampule for use in an automatic sterilization device, and methods for disinfecting a medical instrument employing the inventive antibacterial solution.

Abstract: The present invention relates to novel gastroretentive dosage systems, in particular, a floating capsule which releases the drug without any lag time and which remains buoyant for a sufficient period of time in the stomach. Further, the invention relates to the process of preparation thereof.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: A sterile pharmaceutical composition having as its active principles piperacillin sodium and tazobactam sodium of substantially the same density, mixed with sodium bicarbonate. The mixture is soluble in water to give injectable reconstituted solutions having high stability with time.

Abstract: There is provided a residual mouth alcohol inhibitor configured as an oral composition that absorbs residual mouth alcohol that remains in the mouth of an individual following the consumption of alcohol. The oral composition comprises a combination of sodium bicarbonate, calcium carbonate, parsley, kelp, fructose, citric acid, natural flavors, artificial flavors, maltodextrin, and silicon dioxide whereby the ratio of sodium bicarbonate to calcium bicarbonate in the composition is approximately 1:1 and the ratio of sodium bicarbonate to parsley in the composition is approximately 2:1 and the ratio of parsley to kelp in the composition is approximately 4:1.

Abstract: A pet supplement includes a joint preserving and joint rebuilding composition comprising chicken collagen type II, glucosamine hydrochloride and chondroitin sulfate, a vitamin composition comprising vitamins C, D and K, a mineral composition comprising calcium, magnesium, zinc, copper, manganese and boron, a herbal anti-oxidant cofactor blend comprising citrus bioflavonoids, red grapes anthocyanins, turmeric rhizome, boswellia resin and fennel seed. Each of these ingredients is intimately mixed into the pet supplement and orally delivered to the pet in the form of a segment, paste or powder having a size and weight or other dosage measuring feature adjusted in accordance with the pet's weight. A synergistic action between these ingredients preserves and rebuilds the pet's joints, and is nutritionally beneficial for the pet.

Abstract: Improved nutraceutical compositions and methods for maintaining healthy calcium metabolism and maintenance of muscle mass. The compositions include a first component selected from the group consisting of a citrate anion, a bicarbonate anion and an acetate anion; a second component selected from the group consisting of a potassium cation, a magnesium cation, a calcium cation, and a sodium cation; and a third component selected from the group consisting of resveratrol, green tea extract, tumeric, basil, sage, thyme, ginger or ginger extract, oregano or oregano extract, rosemary or rosemary extract, hypericum perforatum, glycyrrhiza glabra, plantago lanceolata, quercetin, glycyrrhiza glabra, and gingko biloba. The compositions may be administered conventionally in tablets or capsules, as a dietary supplement, or be delivered in a food additive, food or beverage product, functional food, medical food, botanical drug, over-the-counter (OTC) drug, or any other category of product for human or animal consumption.

Abstract: An orally administered composition that includes least one alkaline agent with a pH of at least 9.0 to 12.0, mixed in an aqueous vehicle with relatively high surface tension, high viscosity and lateral adhesion properties. When mixed, a low water soluble emulsion is formed that evenly coats and partially adheres to the lower section of the esophagus and the LES and forms a relatively long acting, protective barrier and partially neutralizes gastric acid. In one embodiment, the alkaline agent is potassium hydroxide and the aqueous vehicle is made of hydroxypropyl methyl cellulose, polyethylene glycol or ethylene glycol and additional thickener agents capable of withstanding high pH environments, such as xanthan gum, croscarmellose sodium, and microcrystalline cellulose. Additional organoleptic agents, such as gum Arabic and polyethylene glycol, flavorings, such as sodium chloride, acesulfame potassium, sodium saccharine, and mint, and stabilizers such as colloidal silica made be added.

Abstract: This invention is concerned with the use of date syrup used as a binder (agglutinant) for solid dosage forms, such as tablets. The features of the granules and the tablets have been studied in comparison with granules and tablets which use different types of agglutinants such as starch paste and sucrose syrup and the results have shown that the use of date syrup as a binder for tablets yields results superior to other kinds of binders. In addition, date syrups gives the granules and tablets a fair color, good taste, distinct and pleasant odor, and it is favorable in regards to shape and taste by patients.

Abstract: An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the agent to raise the pH of the composition to a level of from about 8 to about 12.5 to increase the effectiveness and functional utilization of the agent while the composition is in the person's stomach. In a preferred composition, the electrolyte additive is selected from the group consisting of calcium, magnesium and potassium electrolytes. The supplement composition may be in the form of tablet, capsule, powder or liquid forms. The supplement composition is designed to provide for optimum utilization of a dietary and/or therapeutic supplement agent when taken orally with food or a beverage.

Abstract: The present invention relates to a multi-layer orally disintegrating tablet having (1) an enteric fine granule-containing layer containing a proton pump inhibitor and (2) an acetylsalicylic acid-containing layer, which shows high stability of the active ingredients (proton pump inhibitor, aspirin) and expresses the pharmacological effects of the active ingredients stably and rapidly after administration.

Abstract: A solid oral pharmaceutical composition in the form of at least one tablet, the tablet consisting of a core including at least one bicarbonate salt as active ingredient and at least one prolonged-release matrix, and of a coating including at least one coating agent, the composition allowing continuous release in vivo over a period from after a quarter of an hour and up to twelve hours after taking a single dose, for use thereof as a medicament, in particular in the treatment and/or prevention of urinary lithiasis and related diseases, occurring at a physiological pH and/or during urinary acidosis and/or during hypobicarbonatemia and/or during hypocitraturia and/or during hypercalciuria and/or during hyperoxaluria.

Abstract: The invention relates to a composition for injectable cement, comprising a mineral sold phase, a separate liquid phase and, optionally, microparticles of a biocompatible and biodegradable polymer. The mineral solid phase comprises a mixture of powders with the molar composition: (CP)6 (CaO)y (SrCO3)z, [CP being CaHPO42H2O, CaHPO4, Ca1-xSrxHPO4, an equimolar mixture of bis(Ca(H2PO4)2, H2O and CaO, or a mixture of two or three of said compounds] and y+z=4?1. The liquid phase comprises pure apyrogeneic water or a saline aqueous solution with pH 4 to 9. The ratio L/P [volume of liquid phase/mass of solid mineral phase] is at least 0.4 ml/g. The above is of application as bone replacement.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the agent to raise the pH of the composition to a level of from about 8 to about 12.5 to increase the effectiveness and functional utilization of the agent while the composition is in the person's stomach. In a preferred composition, the electrolyte additive is selected from the group consisting of calcium, magnesium and potassium electrolytes. The supplement composition may be in the form of tablet, capsule, powder or liquid forms. The supplement composition is designed to provide for optimum utilization of a dietary and/or therapeutic supplement agent when taken orally with food or a beverage.

Abstract: The present invention provides therapy and methods for the treatment and prevention of diseases of cell proliferation such as cancer, benign tumors, and viral diseases such as HIV-AIDS, hepatitis B, hepatitis C and cirrhosis. The methods of this invention consist of the administration to a patient of a combination of effective amounts of agents capable of eradicating the neoplastic cells, while sparing the non-neoplastic cells from cytotoxic side-effects. The agents co-administered in therapeutically effective amounts are: chemotherapeutic agents, apoptotic agents, anti-angiogenic agents, cell differentiation agents, immunomodulating agents, antioxidants, vitamins, microelements, enzymes and natural extracts.

Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.

Abstract: The present invention relates to a directly compressible magnesium hydroxide carbonate and to a process for the preparation thereof, and to the use thereof.

Abstract: The present invention provides a pharmaceutical and/or veterinary composition comprising a retard release formulation of a Solarium glaucophyllum preparation. The composition further preferably comprises a calcium source. The composition of the invention is suitable to prevent and/or treat hypocalcaemia. Furthermore, the composition is suitable to prevent milk fever in cows. Advantageously, the composition is administered only once before calving so as to prevent the occurrence of milk fever in cows.

Abstract: A method is provided for preventing or treating bone or musculoskeletal metabolism disorders or kidney malfunction in humans. It comprises providing to a subject in need of that a calcium containing or calcium enriched diet combined with the administration of an efficient amount of a plant extract of Solatium glaucophyllum comprising from about 0.8 to about 2.2 weight % of a mixture of 1,25-dihydroxyvitamin D3 glycosides and quercetin glycosides present in a ratio of about 1:100 to 1:200 parts by weight. There are also provided food or dietary composition and food supplement designed for preventing or treating bone or musculoskeletal metabolism disorders or kidney malfunction in humans which comprises an efficient amount of the said plant extract of Solanum glaucophyllum and a source of calcium.

Abstract: A medicated chewing gum tablet comprising at least two layers, a first layer prepared by compressing a gum base material and tablet base material, and a second layer prepared by compressing a tablet base material, wherein the second layer further comprises an active ingredient being a mineral salt, wherein the mineral is calcium.

Abstract: An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the agent to raise the pH of the composition to a level of from about 8 to about 12.5 to increase the effectiveness and functional utilization of the agent while the composition is in the person's stomach. The supplement composition is designed to provide for optimum utilization of a dietary and/or therapeutic supplement agent when taken orally with food or a beverage.

Abstract: An oral dosage form for administration to an animal comprising a biologically utilizable form of calcium and a extended release system that maintains the calcium level in the animal's bloodstream at a substantially beneficial level for a defined period of time.

Abstract: A composition comprising a powder mixture of potassium citrate and calcium citrate as mixtures of pure chemical salts and methods of making and using the composition are disclosed. The composition is useful for the treatment and prevention of kidney stones and osteoporosis and better delivers potassium and calcium than commonly used potassium and calcium supplements.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage for in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.

Abstract: Three types of trisiloxane surfactants having the basic formula: MDM? are described wherein the substituents on the differing M and M? groups, in conjunction with pendant polyalkylene oxide substituents on the D group render the surfactant resistant to hydrolysis under either basic or acidic conditions outside the pH range of 6.0 to 7.5. The compositions are useful in agricultural, household and cosmetic applications.

Abstract: A substance for use as a medicament, comprises a solid mixed metal compound of formula (I): MII1-aMIIIaObAn?c.zH2O (I) where MII is at least one bivalent metal: MIII bis at least one trivalent metal; An? is at least one n-valent anion; 2+a=2b+?cn; and ?cn<0.9a. The substance may be made by heating at a temperature of from 200° C. to 600° C., preferably from 250° C. to 500° C. of a substance comprising a compound of formula (II): MII1-xMIIIx(OH)2An?y.mH2O (II) where MII is at least one bivalent metal; MIII is at least one trivalent metal; An? is at least one n-valent anion; x=?yn 0<x?0.5, 0<y?1 and 0<m?10.

Abstract: A method is provided for attenuating free radical formation resulting from a bodily insult. The method includes administering bicarbonate to the body of a subject at a dosage ranging from 1.5 mEq/kg of body weight to 5.0 mEq/kg of body weight within a 24-hour period.

Abstract: The invention relates to a method of prevention or treatment of a condition such as magnesium deficiency or deficit or abnormality, creatine or creatine phosphate (phosphocreatine) deficiency or abnormality, parathyroid hormone (PTH) excess or abnormality, sodium deficiency or abnormality, potassium deficiency or abnormality, antidiuretic hormone excess or abnormality or a condition characterised by abnormal levels of parathyroid hormone related protein (PTHrP). In the method, a therapeutic quantity of a neutral to mildly alkaline solution of a magnesium salt comprising bicarbonate ions is administered to the patient.

Abstract: This invention is concerned with the use of date syrup used as a binder (agglutinant) for solid dosage forms, such as tablets. The features of the granules and the tablets have been studied in comparison with granules and tablets which use different types of agglutinants such as starch paste and sucrose syrup and the results have shown that the use of date syrup as a binder for tablets yields results superior to other kinds of binders. In addition, date syrups gives the granules and tablets a fair color, good taste, distinct and pleasant odor, and it is favorable in regards to shape and taste by patients.

Abstract: Disclosed are methods and complexes for increasing magnesium uptake in mammals. Increasing magnesium uptake in mammals is accomplished by concurrently administering one or more magnesium salts with one or more quaternary amines and/or phosphatides and one or more di- or tri-carboxylic acids.

Abstract: A gastric ulcer therapeutic agent comprising as an active ingredient a composite hydroxide of a hydrotalcite and an aluminum hydroxide compound, which composite hydroxide is represented by the formula (1), Mg1-xAlx(OH)2-ny(An-)y/n (H2O)m??(1) wherein An- represents an anion, n represents a valence of the anion in the range of 1 to 4, x is in the range of 0.34<x<0.7, y is in the range of 0<y<0.8, and m is in the range of 0<m<4.

Abstract: Disclosed are various embodiments of edible food compositions effective for neutralizing stomach acid. Further, the present invention is directed toward methods of preparing the edible composition and the methods for reducing stomach acidity by ingesting the edible composition. In one embodiment, the edible composition comprises sweetener, flour, fat, leavening agent, water, and an effective amount of acid neutralizing material. In one embodiment, the above ingredients are combined to form a heavy dough which is then rolled out, divided into sections, and baked, resulting in a cookie with effective antacid properties. Further disclosed are edible compositions for delivering calcium as a dietary supplement.

Abstract: The present invention relates to an anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having a catalytic function; (B) a mixture of a coenzyme having reducing ability and a quinone, and (C) an additive. The anti-bacterial, anti-virus, and anti-fungus composition of the present invention is capable of destroying viruses as well as killing bacterial and fungi. Therefore, the composition can be formulated as an aerosol and a film for applying to protection devices such as respirators, masks, gloves, filters, condoms, etc. The present composition can also be used in household, vehicle, hospital, school, restaurant, hotel, internet coffee shop for applying to filter of air-conditioner, tap, stool, interior of elevator and its keyboard.

Abstract: The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient, and a matrix comprising directly compressible dextrose monohydrate and sucralose, said tablet being substantially fat free and said matrix being substantially free of non-saccharide, water soluble polymeric binders.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: The present invention relates to an anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having a catalytic function; (B) ionic compound, and (C) an additive. The anti-bacterial, anti-virus, and anti-fungus composition of the present invention is capable of destroying viruses as well as killing bacterial and fungi. Therefore, the composition can be formulated as an aerosol and a film for applying to protection devices such as respirators, masks, gloves, filters, condoms, etc. The present composition can also be used in household, vehicle, hospital, school, restaurant, hotel, internet coffee shop for applying to filter of air-conditioner, tap, stool, interior of elevator and its keyboard.

Abstract: The invention is directed to a hybrid inducible release vehicle, to a method for preparing such a vehicle, and to the use thereof. The hybrid inducible release vehicle of the invention comprises a gel, which gel comprises a cross-linked carbohydrate and/or protein polymer and an inorganic carrier, and at least one active ingredient bound to said inorganic carrier, wherein the release of the active ingredient is triggered by contact of the vehicle with an external stimulus.

Abstract: A method for combating unwanted conditions downstream of the mouth with adhering troches. A method to treat or reduce replication of a virus in throat tissues by releasing an anti-viral from an adhering disc. A method to treat sore throat with time release of Glycyrrhiza extract or collagen from an adhering disc. A method to treat sore throat with topically applied cobalamin. An adhering troche that releases antacid, alginate, bismuth subsalicylate, soluble zinc, such as zinc gluconate, bioactive vitamin B12 (methylcobalamin), antibiotic, or anti-viral. A method to combat bacterial effects downstream of the mouth with topically applied xylitol.

Abstract: The present invention provides medicaments useful for reducing phosphorus serum level, especially in those subjects affected from hyperphosphatemia. More specifically, the present invention relates to pharmaceutical compositions to be administered by oral route in fasting periods, in order to absorb phosphorus compounds from fluids of the enteric tract, especially from saliva.

Abstract: A composition comprising an antacid, and a local, topical anesthetic. The composition is used to relieve pain or discomfort associated with a sore throat, and therefore, the invention is also directed to a method of alleviating the pain or discomfort associated with a sore throat comprising instructing a human to orally administer the composition.

Abstract: Saccharide compositions and methods of their use to (a) treat functional bowel disorders, (b) gastroesophageal reflux disease and (c) syndromes of nausea, vomiting and diarrhea in man and animals. Also disclosed are saccharide compositions and methods of their use to accelerate the healing of erosions and ulcerated wounds. These same saccharide compositions allow for co-administration and unimpeded uptake of medications traditionally self-adsorbed to saccharides.